Humanin

WHAT IT IS

Humanin is a 24-amino-acid peptide encoded by a short reading frame inside the mitochondrial 16S rRNA gene, making it one of a growing class of molecules called mitochondrial-derived peptides.

It was first identified in surviving brain tissue from a patient with Alzheimer's disease, where it appeared to protect neurons from cell death in laboratory experiments.

It circulates naturally in the body, and researchers have measured its levels in blood as a way to study connections between mitochondrial signaling and aging. It is not a supplement ingredient with an established consumer track record and is not an approved medication.

WHAT RESEARCHERS ARE STUDYING IT FOR

Published research, mostly in cell cultures, animal models and observational human studies, has examined:

• Protection of neurons from stress in Alzheimer's disease and other neurodegeneration models
• Cell survival and stress-resistance signaling across multiple tissue types
• Associations between circulating humanin levels and markers of metabolic health, cardiovascular disease and longevity
• Insulin sensitivity and glucose metabolism in animal models
• Humanin analogs, chemically modified versions designed to be more potent or stable, tested mainly in animals

PROPOSED BIOLOGICAL MECHANISMS

Humanin is thought to act partly through cell-surface receptor complexes and partly through intracellular pathways that influence whether a stressed cell survives or undergoes programmed cell death.

As a signal that originates from mitochondria, humanin is studied as part of a broader idea called mitochondrial-to-nuclear communication, where the cell's energy-producing organelles send signals that influence gene expression and stress responses elsewhere in the cell.

Researchers have proposed that declining humanin production with age may relate to reduced cellular resilience, though this remains a hypothesis rather than an established causal mechanism.

AREAS OF RESEARCH INTEREST

• Whether circulating humanin levels are a useful biomarker of biological aging
• Whether synthetic humanin analogs could eventually be developed into treatments for neurodegenerative or metabolic disease
• How mitochondrial-derived peptides fit into the broader picture of cellular aging alongside other longevity-related pathways
• Whether exercise and other lifestyle factors influence endogenous humanin levels, an early and still-developing line of inquiry

WHAT THE EVIDENCE CURRENTLY SUGGESTS

Cell and animal studies consistently describe humanin as cytoprotective, meaning it appears to help cells survive various forms of stress in controlled laboratory conditions.

Human research so far is largely observational, correlating blood humanin levels with age, metabolic markers or disease status, rather than testing humanin itself as an administered treatment in controlled human trials.

There is no published evidence that giving people humanin or a humanin analog treats any disease. FDA status: humanin is not FDA-approved as a drug for any condition.